Pacira BioSciences, Inc. PCRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $734.86M+1.2% | $726.41M+1.3% | $716.79M+1.6% | $705.85M+0.4% | $702.77M+0.3% | ||
| $151.86M+1.4% | $149.75M+0.3% | $149.34M-3.0% | $153.92M-2.2% | $157.32M-7.7% | ||
| $583.01M+1.1% | $576.66M+1.6% | $567.46M+2.8% | $551.93M+1.2% | $545.45M+2.8% | ||
| 79.3%0.0pp | 79.4%+0.2pp | 79.2%+1.0pp | 78.2%+0.6pp | 77.6%+1.9pp | ||
| $119.69M+2.3% | $116.96M+13.1% | $103.41M+7.1% | $96.54M+8.9% | $88.68M+8.7% | ||
| $375.93M+1.9% | $368.76M+6.3% | $346.77M+5.3% | $329.3M+6.6% | $308.85M+5.0% | ||
| $57.29M0.0% | $57.29M0.0% | $57.29M0.0% | $57.29M0.0% | $57.29M0.0% | ||
| —— | —— | —— | —— | —— | ||
| $710.76M+0.5% | $707.22M+4.7% | $675.24M-16.7% | $810.18M+2.9% | $787.37M+1.7% | ||
| $24.1M+25.6% | $19.19M— | —— | —— | —— | ||
| 3.3%+0.6pp | 2.6%— | —— | —— | —— | ||
| $16.57M-5.0% | $17.45M-4.3% | $18.23M-2.2% | $18.64M+4.5% | $17.83M+7.6% | ||
| $17.77M-21.8% | $22.73M-12.5% | $25.99M+13.3% | $22.94M+1.1% | $22.68M+15.2% | ||
| -$10.94M-372% | -$2.32M-946% | $274K+112% | -$2.22M-113% | $16.55M+61.3% | ||
| $13.17M-22.0% | $16.87M— | —— | —— | —— | ||
| —— | —— | $20.39M-2.5% | $20.91M-41.4% | $35.69M-2.1% | ||
| $5.14M-27.0% | $7.03M— | —— | —— | —— | ||
| 0.7%-0.3pp | 1%— | —— | —— | —— | ||
| $0.12-20.0% | $0.15— | —— | —— | —— | ||
| $0.12-20.0% | $0.15— | —— | —— | —— | ||
| 175.9M-3.1% | 181.5M-0.7% | 182.7M-0.9% | 184.4M-2.7% | 189.4M-2.9% | ||
| 174.5M-3.2% | 180.3M-0.9% | 182M-1.1% | 184.1M-0.4% | 184.8M-0.1% | ||
| $57.29M0.0% | $57.29M0.0% | $57.29M0.0% | $57.29M0.0% | $57.29M0.0% | ||
| -$11.16M-68.5% | -$6.62M-1.8% | -$6.5M+0.2% | -$6.51M-256% | $4.19M+1,223% | ||
| —— | —— | —— | —— | —— | ||
| $734.86M+1.2% | $726.41M+1.3% | $716.79M+1.6% | $705.85M+0.4% | $702.77M+0.3% | ||
| $24.1M+25.6% | $19.19M— | —— | —— | —— | ||
| $115.29M+4.6% | $110.21M— | —— | —— | —— | ||
| $115.29M+4.6% | $110.21M— | —— | —— | —— | ||
| 15.7%+0.5pp | 15.2%— | —— | —— | —— | ||
| $24.1M+25.6% | $19.19M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pacira BioSciences, Inc.'s revenue?
- Pacira BioSciences, Inc. (PCRX) generated $734.9M in revenue over the trailing twelve months, up 4.6% year over year.
- Is Pacira BioSciences, Inc. profitable?
- Pacira BioSciences, Inc. reported $5.1M in net income over the trailing twelve months, a 0.7% net margin.
- What are Pacira BioSciences, Inc.'s profit margins?
- Gross margin is 79.3% and operating margin is 3.3%, with a 0.7% net margin.
- What is Pacira BioSciences, Inc.'s earnings per share?
- Pacira BioSciences, Inc.'s diluted EPS over the trailing twelve months is $0.12.
- Where does Pacira BioSciences, Inc.'s income statement data come from?
- Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
